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Summary
Purpose: Phase II multicenter study investigated the efficacy and toxicity of the novel halogenated derivative of sulfaquixon-
aline Chloroquinoxaline Sulfonamide (CQS) in metastatic colorectal cancer. Experimental design: Eligible patients with
metastatic or recurrent colorectal cancer received CQS at a dose schedule of 2000 mg/m2 over an hour weekly for 4 weeks
every 42 days. Treatment was continued until unexpected toxicity or disease progression. Results: A total of seventeen patients
were enrolled on this study. 94% of all patients enrolled had prior treatment. Sixteen patients were evaluable for response
with fifteen patients showing evidence of disease progression and one patient with prolonged stable disease. One patient had
non-evaluable disease. Following this interim analysis, the drug was considered ineffective and the study was terminated
early. The most frequent adverse event was anemia. No patients discontinued the treatment because of toxicity. Conclusion:
CQS, when given at a dose of 2000 mg/m2 weekly for 4 weeks every 42 days to patients with metastatic colorectal cancer,
does not result in significant tumor regression.
Introduction
Adenocarcinoma of the colon and rectum is a major health
problem in the United States with approximately 150,000
cases estimated to occur in the year 2005 [1]. One-third of
those patients will die from their disease every year [1].
The overall survival in colorectal cancer is 62% with only
about 8–9% surviving 5 years with metastatic disease [2].
Chemotherapy has been the mainstay of therapy in patients
with metastatic disease with modest effects on survival.
The investigational drug Chloroquinoxaline Sulfonamide
(CQS) is a halogenated derivative of sulfaquixonaline, an
antifungal agent used in the control of coccidiosis in animals
[3]. The mechanism of action of this compound is largely
unknown until recently, although unlike sulfaquixonaline, it
does not interfere with folate homeostasis [4]. In vitro, CQS
acts as a topoisomerases (topo) IIα and IIβ poison, thus
inhibiting DNA replication [5]. CQS was found to induce
arrest of mitogen stimulated lymphocytes in G0/G1 stage
of the cell cycle [5–7]. The antitumor activity of CQS was
first discovered in the human tumor colony-forming assay,
with inhibitory effects against human lung, colon, breast and
other tumor types. In vivo studies of CQS using H82 small
cell lung tumor implanted subcutaneously into athymic mice
resulted in tumor regression when the drug was given via
intraperitoneal and subcutaneous routes for five days [4].
Three phase I studies with CQS were conducted simul-
taneously looking at either a one hour intravenous infusion
every 28 days or a one hour infusion weekly for 4 weeks ev-
ery 42 days [8–10]. Dose limiting toxicities included hypo-
glycemia and supraventricular tachycardias were seen with
doses higher than 4000 mg/m2 given every 28 days. There
were seven minor responses seen in patients with non-small
cell lung cancer (six) and colon cancer (one). Using a weekly
schedule, the MTD was determined to be 2000 mg/m2/wk
[8]. In this study there were a total of three minor responses
in patients with non-small cell lung cancer (two) and col-
orectal cancer (one). In one study, it was shown that when
correcting for protein binding, the equivalent target human
plasma CQS concentration derived from the human tumor
colony-forming assay would be at least 100 µg/ml during a
minimum of 24 h [8].
Based on the evidence of preclinical antitumor activity
and the presence of antitumor activity in colon cancer in
both phase I studies, a phase II study of CQS in patients
with metastatic colorectal cancer was conducted.
Patient and methods
Patient selection
Patients entered on this study had metastatic colorectal can-
cer and measurable disease. Patients were allowed up to
one prior chemotherapy, and in addition could have one
biologic therapy. Patients were also allowed to have had ad-
juvant therapy only if the recurrence was at least six months
after receiving therapy. Additional inclusion criteria were
ECOG performance status of ≤2, normal organ and marrow
function as defined by leukocytes of >3,000/ml, absolute
neutrophil count of >1,500/ml platelets >100,000/ml , to-
tal bilirubin within normal institutional limits , AST and/or
ALT < 2.5 X institutional upper limit of normal and creati-
nine within normal institutional limits.
Treatment
CQS was given using the schedule of 2000 mg/m2 over an
hour weekly for 4 weeks every 42 days. Based on phase I
data, patients on this study were carefully monitored for car-
diac arrhythmias and disturbances in glucose metabolism.
Patients had an ECG strip prior to and after their weekly
treatment during the first cycle and then the first day of each
subsequent cycle. In addition, blood glucose was checked
prior to each treatment and then by fingerstick every 2 h
post treatment for 4 h for the first cycle and for any episode
clinically consistent with hypoglycemia.
Efficacy assessment
Patients were evaluated at baseline and every 12 weeks for
response. Tumor measurements were done by CT scanning
and responses were assessed using RECIST criteria [11].
Safety assessment
Toxicity was assessed using the NCI Common Toxicity Cri-
teria (CTC) version 2.0
Pharmacokinetic analysis
We performed limited pharmacokinetics based on the re-
sults of the phase I studies [8–10]. Pharmacokinetic anal-
ysis was performed at 0, 2 and 24 h following the first
dose of CQS administration. Samples were obtained from
3 patients. Serum analysis of CQS levels was performed
using the HPLC method previously described [3, 8]. Es-
sentially, various amounts of CQS were added to 0.5 ml
of blank human plasma to result in concentrations rang-
ing between 500 and 4000 ng/ml and R-XK469 {(2-[4-(7-
Chloro-2-quinoxaliny) oxy] phenoxy propionic acid)} was
used as the internal standard, to result in a concentration
of 1 µg/ml. These solutions were used to construct a cal-
ibration curve. For plasma samples 0.5 ml was used with
the concentration of internal standard used kept constant at
1 µg/ml. Plasma proteins were precipitated by use of 2.5
ml of acetonitrile. After centrifugation at 1500 g, the su-
pernatant was removed and evaporated under a stream of
nitrogen. The residue was reconstituted in 200 µl of mobile
phase and a 50 µl aliquot was analyzed for CQS by HPLC.
The mobile phase consisted of 30% methanol containing 20
mM ammonium nitrate and 0.2% acetic acid. The flow rate
was 1 ml/min and the components were detected by UV
at 330 nm. HPLC was typically run for 30–40 min. Under
the stated condition, the typical retention times were 20.8
min for R-XK469 and 24.15 min for CQS, with no other
major peaks in the chromatogram up to 40 min elution time.
No attempt was made to locate and identify CQS metabo-
lites. The assay was linear from 0.5 to 4000 µg/ml. of CQS
using 0.5 ml plasma. The within day reproducibility was
evaluated at 0.5, 1 and 2 µg/ml concentrations with shown
percent CV values of 3.9,5.5 and 9.2 respectively (n = 6).
The corresponding accuracy percent values 96.3, 90.9 and
85.6 respectively.
Statistical considerations
This was a minimax two-stage design of Simon with the
primary endpoint being overall response rate. In this design
we considered CQS to be uninteresting or ineffective if
the true response probability was less than 20%.The two-
stage design establishes that if 3 or fewer responses are
seen in the first 19 response-evaluable patients, the study




The majority of patients (94%) had received prior
chemotherapy (Table 1). The most commonly used regi-
mens were 5FU and CPT-11. The rest of the characteristics
are listed in Table 1.
Objective response
Sixteen patients were evaluable for response with fifteen
patients showing evidence of disease progression and one
patient with prolonged stable disease. One patient had non-















Prior therapy 94% (16/17)
Participating sites
Cleveland Clinic 8/17
Ohio State Univ 3/17
University of MI 3/17
Central Baptist 3/17
evaluable disease. Following this interim analysis, the drug
was considered ineffective and the study was terminated
early.
Safety
Toxicities from this drug at the dose tested were very mild..
Most common toxicities included anemia (24%), constipa-
tion (18%), hypoglycemia, leukopenia, flushing, stomatitis,
sensory neuropathy, headache and fatigue (12%). Only 1
patient had grade 3 toxicity with urticaria. No patients had
grade 4 toxicity on this study. For a full list of toxicities ,
please refer to Table 2.
Pharmacokinetic analysis
Three patients were studied and the results are shown in
Figure 1. Essentially, serum CQS levels were consistently
below the therapeutic target of 100 µg/ml in the first 24 h
after the CQS dose administered.
Discussion
This phase II study of the novel compound Chloroquinox-
aline Sulfonamide (CQS)–a halogenated derivative of
sulfaquixonaline- in patients with advanced colorectal
cancer was initiated based on promising in vitro and in
vivo anticancer activity as well as some anticancer activity
in a prior phase I study [8]. In this study we showed
that CQS given at 2000 mg/m2 over an hour weekly for




grades Grade 1 Grade 2 Grade 3 Grade 4
Anemia 24% (4) 24% (4)
Constipation 18% (3) 18% (3)
Hypoglycemia 12% (2) 12% (2)
Sensory
Neuropathy
12% (2) 12% (2)
Flushing 12% (2) 12% (2)
Stomatitis 12% (2) 12% (2)
Fatigue 12% (2) 6% (1) 6% (1)
Headache 12% (2) 12% (2)
Leucopenia 12% (2) 12% (2)
Lymphopenia 6% (1) 6% (1)
Urticaria 6% (1) 6% (1)
Nausea 6% (1) 6% (1)
Hyperglycemia 6% (1) 6% (1)
Ataxia 6% (1) 6% (1)
Fever 6% (1) 6% (1)
Musculoskeletal
pain
6% (1) 6% (1)
VZV
reactivation∗
6% (1) 6% (1)
DVTˆ 6% (1) 6% (1)
*Varicella zoster reactivation
†Deep venous thromobosis
Figure 1. Pharmacokinetics of CQS at 0, 2 and 24 hours after the ad-
ministration of the first dose of CQS. The limited sampling was performed
on only 3 patients.
4 weeks every 42 days was well tolerated but lacked
clinical activity in patients with metastatic colorectal
cancer.
The lack of efficacy in this study might possibly be related
to one or more of the following: (1) All 3 patients included
in the pharmacokinetic analysis failed to achieve the target
serum level of 100 µg/ml in the first 24 h. However, this
was a limited pharmacokinetic analysis (as intended by the
study design), and data from all patients were not available.
However, a previously published study looking at CQS with
the same dose/schedule in patients with non-small cell lung
cancer showed no activity of the drug despite that the target
concentration being achieved in 90% of the patients fol-
lowing dose readjustments in a number of those patients.
(2) The fact that most patients had been exposed to prior
therapy. It is well known that second line therapy in col-
orectal cancer is largely ineffective with response rates of
less than 10% [12, 13]. Our study was designed to consider
a response rate of at least 20% as interesting, approximately
double the response rate seen with “active” therapies in the
second-line setting [12, 13]. Perhaps this response rate of
interest was too ambitious, resulting in an underestimation
of the activity of this drug. (3) As noted before, CQS inhibits
both topo IIα and IIβ [5]. Published in vivo data suggests
a good rationale for targeting topo II in colorectal cancer
based on a higher level of expression of topo IIα gene in
tumors relative to normal tissue [14]. However, this study
suggested that the sequential chemotherapy targeting topo I
and topo II enzymes by modulating topo IIα expression by
topo I inhibitors might be more effective in colon cancer, in
terms of their relationship between topo I and topo IIα ex-
pression in tumor cells [14]. Perhaps, an improved strategy
might be to use this drug is in sequence with a topo I in-
hibitor such as irinotecan, a drug with activity in colorectal
cancer.
In conclusion, CQS given intravenously at 2000 mg/m2
over an hour weekly for 4 weeks every 42 days was well
tolerated but lacked noticeable activity in patients with
metastatic colorectal cancer. This lack of activity might be
related to one on more element as noted above, however,
further study of CQS at this dose and schedule cannot be
recommended.
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